E Matsuura Selected Research

beta 2-Glycoprotein I (Apolipoprotein H)

5/2010	High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome.
4/2010	Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome.
12/2008	Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease?
1/2007	Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages.
3/2006	Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome.
1/2006	Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome.
1/2006	Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis.
1/2005	Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis.
6/2003	IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome.
1/2003	Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

E Matsuura Research Topics

Disease

16	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 05/2010 - 02/2000
12	Thrombosis (Thrombus) 04/2010 - 04/2000
11	Atherosclerosis 04/2010 - 04/2000
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2010 - 01/2005
3	Inflammation (Inflammations) 05/2010 - 01/2006
2	Thrombophilia 05/2010 - 03/2006
2	Infections 11/2009 - 01/2008
2	Autoimmune Diseases (Autoimmune Disease) 10/2008 - 01/2008
2	Vascular System Injuries 10/2008 - 01/2006
2	Meningitis 05/2001 - 02/2000
1	Leukemia 09/2013
1	Acute Coronary Syndrome 09/2012
1	Type 2 Diabetes Mellitus (MODY) 09/2012
1	Vascular Diseases (Vascular Disease) 04/2010
1	Neoplasms (Cancer) 07/2007
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2006
1	Diabetes Mellitus 01/2005
1	Chronic Renal Insufficiency 01/2005
1	Systemic Scleroderma (Systemic Sclerosis) 01/2005
1	Fungal Meningitis 05/2001
1	Viral Meningitis 05/2001
1	Meningeal Tuberculosis (Tuberculous Meningitis) 05/2001
1	Pulmonary Tuberculosis 05/2001
1	Vasculitis (Vasculitides) 05/2001
1	Bacterial Meningitis 05/2001
1	Habitual Abortion (Recurrent Miscarriage) 04/2001
1	Spontaneous Abortion (Miscarriage) 04/2001
1	Nervous System Diseases (Neurological Disorders) 03/2001
1	POEMS Syndrome (Syndrome, POEMS) 03/2001
1	Meningoencephalitis 02/2000
1	Atherosclerotic Plaque (Atheroma) 01/2000

Drug/Important Bio-Agent (IBA)

12	beta 2-Glycoprotein I (Apolipoprotein H)IBA 05/2010 - 10/2000
11	Immunoglobulin G (IgG)IBA 05/2010 - 04/2001
11	AntibodiesIBA 05/2010 - 01/2000
11	oxidized low density lipoproteinIBA 05/2010 - 05/2001
9	AutoantibodiesIBA 05/2010 - 04/2000
5	Antiphospholipid AntibodiesIBA 05/2010 - 04/2000
3	LDL Lipoproteins (beta Lipoproteins)IBA 05/2010 - 03/2006
3	Immunoglobulin M (IgM)IBA 01/2007 - 01/2005
3	Anticardiolipin AntibodiesIBA 01/2003 - 04/2000
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2012 - 09/2012
2	AntioxidantsIBA 09/2012 - 05/2010
2	Lipoproteins (Lipoprotein)IBA 05/2010 - 03/2006
2	LipidsIBA 05/2010 - 06/2003
2	7-ketocholesteryl-9-carboxynonanoateIBA 03/2006 - 05/2001
2	AntigensIBA 01/2003 - 05/2001
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2001 - 03/2001
2	Tissue Inhibitor of Metalloproteinase-1IBA 03/2001 - 02/2000
2	Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA 09/2000 - 04/2000
1	Core Binding Factors (Core-Binding Factor)IBA 09/2013
1	Thromboxane B2IBA 09/2012
1	ThromboxanesIBA 09/2012
1	Biomarkers (Surrogate Marker)IBA 09/2012
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 05/2010
1	HDL LipoproteinsIBA 05/2010
1	CholesterolIBA 05/2010
1	C-Reactive ProteinIBA 05/2010
1	Apoprotein(a) (Apolipoprotein (a))IBA 05/2010
1	Apolipoproteins B (ApoB)IBA 05/2010
1	ApolipoproteinsIBA 05/2010
1	Triglycerides (Triacylglycerol)IBA 05/2010
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2009
1	Apolipoproteins E (ApoE)IBA 11/2009
1	Lipopolysaccharide ReceptorsIBA 12/2008
1	EpitopesIBA 01/2008
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2007
1	Aryldialkylphosphatase (Paraoxonase)IBA 03/2006
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2005
1	LigandsIBA 06/2003
1	DNA (Deoxyribonucleic Acid)IBA 04/2001
1	AnticoagulantsIBA 04/2001
1	Matrix Metalloproteinases (MMPs)IBA 03/2001
1	Tissue Inhibitor of MetalloproteinasesIBA 03/2001
1	Hemostatics (Antihemorrhagics)IBA 10/2000
1	AutoantigensIBA 10/2000
1	Prothrombin (Factor II)IBA 09/2000
1	PhosphatidylserinesIBA 09/2000
1	Fibrinolysin FDA Link 08/2000
1	Phospholipids (Phosphatides)FDA LinkGeneric 08/2000
1	Tissue Inhibitor of Metalloproteinase-2IBA 02/2000
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 02/2000
1	Metalloproteases (Metalloproteinases)IBA 02/2000

Therapy/Procedure

1	Immunotherapy 07/2007
1	Therapeutics 05/2001